WallStreetZenWallStreetZen

NASDAQ: SLGL
Sol Gel Technologies Ltd Stock

$0.83-0.09 (-9.78%)
Updated Jun 21, 2024
SLGL Price
$0.83
Fair Value Price
$0.06
Market Cap
$23.12M
52 Week Low
$0.63
52 Week High
$4.05
P/E
-1x
P/B
0.71x
P/S
15.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.72M
Earnings
-$22.86M
Gross Margin
100%
Operating Margin
-1,329.13%
Profit Margin
-1,329.1%
Debt to Equity
0.22
Operating Cash Flow
N/A
Beta
0.57
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SLGL Overview

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SLGL ($0.83) is overvalued by 1,237.55% relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLGL ($0.83) is not significantly undervalued (1,237.55%) relative to our estimate of its Fair Value price of $0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLGL due diligence checks available for Premium users.

Be the first to know about important SLGL news, forecast changes, insider trades & much more!

SLGL News

Valuation

SLGL fair value

Fair Value of SLGL stock based on Discounted Cash Flow (DCF)
Price
$0.83
Fair Value
$0.06
Overvalued by
1,237.55%
SLGL ($0.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLGL ($0.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SLGL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1x
Industry
-5.75x
Market
30.75x

SLGL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
6.2x
SLGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SLGL's financial health

Profit margin

Revenue
$466.0k
Net Income
-$6.3M
Profit Margin
-1,361.4%
SLGL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$39.9M
Liabilities
$7.3M
Debt to equity
0.22
SLGL's short-term assets ($36.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLGL's short-term assets ($36.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLGL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

SLGL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SLGL$23.12M-9.59%-1.00x0.71x
PHGE$23.25M+0.60%-0.55x-2.44x
GANX$23.29M-0.77%-0.86x2.69x
GDTC$22.85M+3.13%-6.90x2.76x
EQ$23.41M0.00%-1.90x1.11x

Sol Gel Technologies Stock FAQ

What is Sol Gel Technologies's quote symbol?

(NASDAQ: SLGL) Sol Gel Technologies trades on the NASDAQ under the ticker symbol SLGL. Sol Gel Technologies stock quotes can also be displayed as NASDAQ: SLGL.

If you're new to stock investing, here's how to buy Sol Gel Technologies stock.

What is the 52 week high and low for Sol Gel Technologies (NASDAQ: SLGL)?

(NASDAQ: SLGL) Sol Gel Technologies's 52-week high was $4.05, and its 52-week low was $0.63. It is currently -79.51% from its 52-week high and 31.54% from its 52-week low.

How much is Sol Gel Technologies stock worth today?

(NASDAQ: SLGL) Sol Gel Technologies currently has 27,857,620 outstanding shares. With Sol Gel Technologies stock trading at $0.83 per share, the total value of Sol Gel Technologies stock (market capitalization) is $23.12M.

Sol Gel Technologies stock was originally listed at a price of $13.64 in Feb 1, 2018. If you had invested in Sol Gel Technologies stock at $13.64, your return over the last 6 years would have been -93.91%, for an annualized return of -37.28% (not including any dividends or dividend reinvestments).

How much is Sol Gel Technologies's stock price per share?

(NASDAQ: SLGL) Sol Gel Technologies stock price per share is $0.83 today (as of Jun 21, 2024).

What is Sol Gel Technologies's Market Cap?

(NASDAQ: SLGL) Sol Gel Technologies's market cap is $23.12M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sol Gel Technologies's market cap is calculated by multiplying SLGL's current stock price of $0.83 by SLGL's total outstanding shares of 27,857,620.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.